MLPSC Therapy for LVAD Gastrointestinal Bleeding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Patients with left ventricular assist devices (LVADs) experience frequent rehospitalizations due to gastrointestinal bleeding and infections, which are significant clinical challenges.

Innovation Solution

Administration of mesenchymal lineage precursor or stem cells (MLPSCs) to subjects with LVAD complications, which reduces gastrointestinal bleeding and related hospitalizations.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If LVAD implantation is performed to treat advanced heart failure, then patient survival is improved, but gastrointestinal bleeding occurs more frequently

Engineering Contradiction:

Improvepatient survivalVSAvoidgastrointestinal bleeding

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces mesenchymal lineage precursor cells as an intermediary substance that mediates between the LVAD implantation and the harmful gastrointestinal bleeding. These cells are administered to patients and work as a biological mediator to reduce GI bleeding while allowing the LVAD to continue providing cardiac support, thus resolving the contradiction between survival benefit and bleeding harm

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biological parameter of the patient's system by introducing stem cells that modulate inflammation and tissue repair. This parameter change in the patient's biological state reduces the harmful effect of GI bleeding while maintaining the beneficial effect of LVAD therapy, thereby resolving the contradiction

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If optimal medical therapy is administered for advanced heart failure, then heart failure symptoms are managed, but gastrointestinal bleeding and infections occur frequently leading to rehospitalization

Engineering Contradiction:

Improveheart failure managementVSAvoidrehospitalization frequency

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The mesenchymal lineage precursor cells serve as an additional intermediary that addresses the root causes of rehospitalization (GI bleeding and infections) while the standard heart failure management continues to handle symptoms. This dual approach improves reliability by reducing rehospitalization while maintaining ease of operation through continued use of established therapies

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The stem cell therapy provides multi-functionality by simultaneously reducing GI bleeding, preventing infections, and potentially improving cardiac tissue health. This universal beneficial effect reduces multiple causes of rehospitalization while working alongside standard heart failure management, thereby improving reliability without complicating the management approach

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250161365A1Method for treating or preventing gastrointestinal bleeding

Publication Date: 2025.05.22 MESOBLAST INTERNATIONAL SARL

AI summary

The present disclosure relates to method of treating or preventing gastrointestinal (GI) bleeding in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).